[HTML][HTML] 非病毒载体递送CRISPR/Cas9 系统的研究进展
王钰， 黄归， 杨菡， 张学农 - 药学学报, 2020 - html.rhhz.net
… 除了修饰主动靶向配体增强载体的主动靶向性, Dong等 [43] 受脂蛋白启发, 设计了一种脂肽纳米
粒(lipopeptide nanoparticles, LPN)用于siRNA的选择性递送.脂肽是以氨基酸,寡肽或多肽作为…
粒(lipopeptide nanoparticles, LPN)用于siRNA的选择性递送.脂肽是以氨基酸,寡肽或多肽作为…
[PDF][PDF] 可电离脂质及其对载核酸药物脂质纳米粒转染效率和安全性的影响研究进展# br
何凤阳， 刘媛媛， 孟庆斌， 刘许歌… - 中国药理学与毒理学 …, 2024 - cjpt.magtechjournal.com
… Lipopeptide nanoparticles for potent and selective siRNA deliv⁃ ery in rodents and nonhuman
primates[J]. Proc Natl Acad Sci USA, 2014, 111(11): 3955-3960. [38] Zhao XW, Chen JJ, …
primates[J]. Proc Natl Acad Sci USA, 2014, 111(11): 3955-3960. [38] Zhao XW, Chen JJ, …
[PDF][PDF] siRNA 用于癌症治疗的递送载体设计策略
刘颖， 赵俐 - 医药导报, 2018 - yydbzz.com
… Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and
nonhuman primates [J].Proc Natl Acad Sci U S Aꎬ2014ꎬ111(11):3955-3960. [8] SCHAFFERT …
nonhuman primates [J].Proc Natl Acad Sci U S Aꎬ2014ꎬ111(11):3955-3960. [8] SCHAFFERT …
[HTML][HTML] 微流控技术在纳米药物输送系统中的应用
郭希颖， 魏巍， 王坚成， 张强 - 药学学报, 2017 - html.rhhz.net
… of nanoparticles, which are difficult to be achieved by the conventional methods. Based on
the progress in delivery … delivery system such as liposomes, polymer nanoparticles and hybrid …
the progress in delivery … delivery system such as liposomes, polymer nanoparticles and hybrid …
[PDF][PDF] 首例RNA 干扰药物问世及该领域技术演化历程
黄渊余 - Progress in Biochemistry and Biophysics, 2019 - researchgate.net
… Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman
primates. Proc Natl Acad Sci USA, 2014,111(11): 3955-3960 [47] Morrissey DV, Lockridge …
primates. Proc Natl Acad Sci USA, 2014,111(11): 3955-3960 [47] Morrissey DV, Lockridge …
[PDF][PDF] 基因递送中阳离子脂质体结构对转染效率及细胞毒性的影响研究进展
邢浩宇， 孙洁芳， 董慧胜， 高千龙… - 中国药理学与毒 …, 2024 - cjpt.magtechjournal.com
… Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman
primates[J]. Proc National Acad Sci, 2014, 111(11): 3955-3960. [49] Kauffman KJ, Dorkin JR…
primates[J]. Proc National Acad Sci, 2014, 111(11): 3955-3960. [49] Kauffman KJ, Dorkin JR…